Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Lisata Therapeutics Inc (LSTA)

Lisata Therapeutics Inc (LSTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y Zacks Investment Research - Thu Nov 7, 11:14AM CST

Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a...

FOLD : 10.98 (-2.31%)
ESPR : 2.11 (-4.52%)
CRSP : 51.88 (+2.29%)
LSTA : 2.91 (-0.34%)
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration GlobeNewswire - Wed Nov 6, 8:23AM CST

LSTA : 2.91 (-0.34%)
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024 GlobeNewswire - Wed Nov 6, 7:30AM CST

LSTA : 2.91 (-0.34%)
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events GlobeNewswire - Thu Oct 31, 7:30AM CDT

LSTA : 2.91 (-0.34%)
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis GlobeNewswire - Mon Oct 28, 7:30AM CDT

LSTA : 2.91 (-0.34%)
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events GlobeNewswire - Thu Oct 3, 7:00AM CDT

LSTA : 2.91 (-0.34%)
Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers PR Newswire - Tue Aug 15, 2023

/PRNewswire/ -- Impilo Therapeutics, Inc. ("Impilo"), a privately held drug discovery and development company, today announced that it has launched with the...

LSTA : 2.91 (-0.34%)

Barchart Exclusives

1 Energy Dividend Stock That Just Hiked Its Cash Flow Forecast Barchart - Thu Nov 7, 6:30PM CST
Analysts are optimistic about this dividend-paying energy company, which raised its cash flow forecast after surging LNG demand pushed it past Q3 expectations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot